Table 1.
Baseline characteristics of the sample.
| Variable | Patients = 74 Aneurysms = 96 |
|---|---|
| Age (in years, mean ± SD) | 64.7 ± 12.4 |
| Women (%) | 60 (81) |
| Smoking (%) | 40 (54.1) |
| Hypertension (%) | 41 (55.4) |
| Diabetes (%) | 12 (16.2) |
| Hyperlipidemia (%) | 32 (43.2) |
| Family history of intracranial aneurysms (%) | 7 (9.5) |
| History of previous SAH (%) | 4 (5.4) |
| Aspirin* | 39 (52.7) |
| Size (in mm, mean, range) | 8.1 (3-27) |
| - ≥7 mm (%) | 48 (50.0) |
| - <7 mm (%) | 48 (50.0) |
| Location | |
| - Internal carotid artery (%) | 25 (26.0) |
| - Anterior communicating artery (%) | 16 (16.7) |
| - Anterior cerebral artery (%) | 5 (5.2) |
| - Middle cerebral artery (%) | 26 (27.1) |
| - Posterior communicating artery (%) | 5 (5.2) |
| - Basilar artery (%) | 15 (15.6) |
| - Superior cerebellar (%) | 3 (3.1) |
| - Vertebral artery (%) | 1 (1.0) |
| Aneurysmal wall enhancement† | |
| - Positive | 59 (61.5%) |
| - Negative | 37 (38.5%) |
mm: millimeters; SD: standard deviation
*
Refers to daily intake of ≥81 mg of aspirin during the last 6 months.
†
Defined as positive if aneurysm-to-pituitary stalk contrast ratio (CRstalk) > 0.60.